Drug development company Mesoblast could be unable to continue as a going concern if it cannot successfully raise capital before the end of this week, auditors from PwC warn.
Mesoblast’s share price has declined 84 per cent from $4.54 on December 14 to $2.46 when trading closed last Thursday.
Loading...
Lucas Baird is a journalist based in The Australian Financial Review's Sydney office. Connect with Lucas on Twitter. Email Lucas at lucas.baird@afr.com
